Andrew A Moshfeghi
Overview
Explore the profile of Andrew A Moshfeghi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moshfeghi A, Khurana R, Moini H, Sherman S, Reed K, Boucher N, et al.
BMC Ophthalmol
. 2024 May;
24(1):229.
PMID: 38822279
Background: This study evaluated impact of anti-vascular endothelial growth factor (VEGF) treatment on proliferative diabetic retinopathy (PDR) development among patients with non-proliferative diabetic retinopathy (NPDR) in US real-world clinical practice....
2.
Nguyen Q, Moshfeghi A, Lim J, Ponomareva E, Chauhan A, Rao R, et al.
BMJ Open Ophthalmol
. 2023 Jun;
8(1).
PMID: 37278412
Objective: A simulation model was constructed to assess long-term outcomes of proactively treating severe non-proliferative diabetic retinopathy (NPDR) with anti-vascular endothelial growth factor (anti-VEGF) therapy versus delaying treatment until PDR...
3.
Pitcher 3rd J, Moshfeghi A, Lucas G, Boucher N, Moini H, Saroj N
J Vitreoretin Dis
. 2023 Apr;
5(2):108-113.
PMID: 37009083
Purpose: We assessed the effect of treatment frequency with intravitreal antivascular endothelial growth factor (anti-VEGF) agents on visual acuity (VA) in diabetic macular edema (DME). Methods: This retrospective analysis assessed...
4.
Moshfeghi A, Pitcher J, Lucas G, Boucher N, Saroj N
J Vitreoretin Dis
. 2023 Apr;
5(3):221-226.
PMID: 37006507
Purpose: This work evaluates dosing frequency with intravitreal antivascular endothelial growth factor (anti-VEGF) agents over 2 years and visual acuity (VA) outcomes in neovascular age-related macular degeneration (nAMD). Methods: This...
5.
OFee J, Juliano J, Moshfeghi A
Graefes Arch Clin Exp Ophthalmol
. 2022 Feb;
260(7):2191-2200.
PMID: 35192029
Purpose: To identify factors associated with diabetic macular edema (DME) and to characterize the types of DME present in eyes with proliferative diabetic retinopathy (PDR). Methods: Observational, retrospective case series...
6.
Kushner-Lenhoff S, Kogachi K, Mert M, Chu Z, Shahidzadeh A, Palejwala N, et al.
PLoS One
. 2022 Jan;
17(1):e0262996.
PMID: 35081154
Purpose: To validate retinal capillary density and caliber associations with diabetic retinopathy (DR) severity in different clinical settings. Methods: This cross-sectional study assessed retinal capillary density and caliber in the...
7.
Rosenblatt T, Vail D, Saroj N, Boucher N, Moshfeghi D, Moshfeghi A
Ophthalmic Surg Lasers Imaging Retina
. 2021 Jan;
52(1):29-36.
PMID: 33471912
Background And Objective: To provide an updated estimate of incidence and prevalence of the foremost retinal diseases in the U.S. Patients And Methods: Retrospective study of the Vestrum Health Database...
8.
Moshfeghi A, Lanitis T, Kropat G, Kuznik A, Gibson A, Feng H, et al.
Ophthalmic Surg Lasers Imaging Retina
. 2020 Apr;
51(4):S6-S14.
PMID: 32348529
Background And Objective: To estimate the social cost of blindness due to wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) in the United States...
9.
Lifton J, Moshfeghi A
Ophthalmic Surg Lasers Imaging Retina
. 2020 Jan;
51(1):11-20.
PMID: 31935298
Background And Objective: To evaluate a novel digital method of metamorphopsia quantification in patients with symptomatic visual distortion as determined by M-CHARTS. Patients And Methods: In this institutional review board-approved,...
10.
Moshfeghi A, Thompson D, Berliner A, Saroj N
Ophthalmol Retina
. 2020 Jan;
4(5):481-485.
PMID: 31924543
Purpose: To evaluate the impact of cataract surgery on visual and anatomic outcomes in patients with diabetic macular edema treated with intravitreal aflibercept injection (IAI) or laser control and who...